Article Sidebar

Submitted
Nov 15, 2024
Published
Nov 15, 2024
Download
PDF
Statistic
Read Counter : 12 Download : 9

Main Article Content

Abstract

Pancreatic cancer stands as one of the most daunting challenges in oncology, characterized by high mortality rates and limited progress in treatment outcomes over decades. A critical barrier to improving survival lies in the difficulty of early detection and prevention: symptoms often do not manifest until the disease has reached an advanced stage and reliable screening methods are lacking. This delayed diagnosis contributes significantly to the poor prognosis associated with pancreatic cancer. Genetically, pancreatic tumors exhibit a limited repertoire of frequently mutated genes, including KRAS, CDKN2A (p16), TP53, and SMAD4. Neoadjuvant therapies are being explored to downstage tumors and increase the likelihood of successful surgery. Despite advancements in treatment strategies, including novel drug combinations and multimodal approaches, disease recurrence following surgery remains common, highlighting the urgent need for innovative therapeutic approaches. We summarize the existing knowledge on the critical pathophysiological, molecular, translational, and clinical aspects of pancreatic cancer. Additionally, we outline potential future directions for research and patient management in this challenging disease.

Keywords

Pancreas Pancreatic cancer Biomarker Treatment

Article Details

How to Cite
Vasuki M, Ponmadasamy M, Muthukumar J, Muthukumar S, Vinayakamurthi M.R, & Venkata Rathina Kumar T. (2024). Pancreatic Cancer: Emerging Trends In Diagnosis, Treatment And Future Directions. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(4), 594-604. Retrieved from https://ijrpp.com/ijrpp/article/view/593
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87‐108.
  2. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424.
  3. 3. Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Cancer Netw. 2019;17(5.5):603‐605.
  4. 4. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977‐988.
  5. 5. Saha SK, Khuda‐Bukhsh AR. Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti‐cancer drugs: current trends. Eur J Pharmacol. 2013;714(1‐3):239‐248.
  6. 6. Narcis Octavian Zarnescu, Isam W Nasr, Mario Lora, A James Moser. Pancreatic Cancer. Textbook of Surgical Oncology. 2011;488-502
  7. 7. T.J. Grant, K. Hua, A. Singh, Molecular pathogenesis of pancreatic cancer, Prog. Mol. Biol. Transl. Sci. 144 (2016) 241–275.
  8. 8. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, M. Perucho, Most human carcinomas of the exocrine pancreas contain mutant cK-ras genes, Cell 53 (1988) 549–554.
  9. 9. Y. Miyamoto, A. Maitra, B. Ghosh, U. Zechner, P. Argani, C.A. IacobuzioDonahue, V. Sriuranpong, T. Iso, I.M. Meszoely, M.S. Wolfe, R.H. Hruban, D. U. Hani et al. Journal of Drug Delivery Science and Technology 63 (2021) 102539 16 W. Ball, R.M. Schmid, S.D. Leach, Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis, Canc. Cell 3 (2003) 565–576.
  10. 10. J. Zinczuk, ´ K. Zaręba, K. Guzinska-Ustymowicz, ´ B. Kędra, A. Kemona, A. Pryczynicz, p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic, Ir. J. Med. Sci. 187 (2018) 629–637.
  11. 11. J.Z. Xu, W.Q. Wang, W.H. Zhang, H.X. Xu, H.L. Gao, S.R. Zhang, C.T. Wu, S. Li, H. Li, J. Xu, X.J. Yu, L. Liu, The loss of SMAD4/DPC4 expression associated with a strongly activated hedgehog signaling pathway predicts poor prognosis in resected pancreatic cancer, J. Canc. 10 (2019) 4123.
  12. 12. J.B. Fagman, D. Ljungman, P. Falk, B.M. Iresjo, ¨ C. Engstrom, ¨ P. Naredi, K. Lundholmet, EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival, Oncol. Lett. 17 (2019) 5361–5368.
  13. 13. D. Murthy, K.S. Attri, P.K. Singh, Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics, Front. Physiol. 9 (2018) 335.
  14. 14. Y. Bai, Y. Bai, J. Dong, Q. Li, Y. Jin, B. Chen, M. Zhou, Hedgehog signaling in pancreatic fibrosis and cancer, Medicine 95 (2016).
  15. 15. F.H. Sarkar, S. Banerjee, Y. Li, Pancreatic cancer: pathogenesis, prevention and treatment, Toxicol. Appl. Pharmacol. 224 (2007) 326–336.
  16. 16. I. Kuzmickiene, R. Everatt, D. Virviciute, A. Tamosiunas, R. Radisauskas, R. Reklaitiene, E. Milinaviciene, Smoking and other risk factors for pancreatic cancer: a cohort study in men in Lithuania, Cancer Epidemiol. 37 (2013) 133–139.
  17. 17. M. Xu, X. Jung, O.J. Hines, G. Eibl, Y. Chen, Obesity and pancreatic cancer: overview of epidemiology and potential prevention by weight loss, Pancreas 47 (2018) 158.
  18. 18. P.Y. Lu, L. Shu, S.-S. Shen, X.-J. Chen, X.-Y. Zhang, Dietary patterns and pancreatic cancer risk: a meta-analysis, Nutrients 9 (2017) 38.
  19. 19. D.S. Michaud, A. Vrieling, L. Jiao, J.B. Mendelsohn, E. Steplowski, S.M. Lynch, J. Wactawski-Wende, A.A. Arslan, H.B. Bueno-de-Mesquita, C.S. Fuchs, Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan), Cancer Causes Control 21 (2010) 1213–1225.
  20. 20. I.A. Ojajarvi, ¨ T.J. Partanen, A. Ahlbom, P. Boffetta, T. Hakulinen, N. Jourenkova, T.P. Kauppinen, M. Kogevinas, M. Porta, H.U. Vainio, E. Weiderpass, C. H. Wesseling, Occupational exposures and pancreatic cancer: a meta-analysis, Occup. Environ. Med. 57 (2000) 316–324.
  21. 21. N. Howlader, A.M. Noone, M. Krapcho, D. Miller, A. Brest, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin, SEER Cancer Statistics Review 1975-2015 4, National Cancer Institute, Bethesda, MD, 2018, p. 2016.
  22. 22. D.K. Andersen, M. Korc, G.M. Petersen, G. Eibl, D. Li, M.R. Rickels, S.T. Chari, J. L. Abbruzzese, Diabetes, pancreatogenic diabetes, and pancreatic cancer, Diabetes 66 (2017) 1103–1110.
  23. 23. S.H. Olson, R.C. Kurtz, Epidemiology of pancreatic cancer and the role of family history, J. Surg. Oncol. 107 (2013) 1–7.
  24. 24. R.A. Osmani, P.K. Kulkarni, D.V. Gowda, U. Hani, V.K. Gupta, M. Prerana, C. Saha, Cyclodextrin-based nanosponges in drug delivery and cancer therapeutics: new perspectives for old problems, in: Applications of Nanocomposite Materials in Drug Delivery, Woodhead Publishing, 2018, pp. 97–147.
  25. 25. R.A.Osmani, U. Hani, R.R. Bhosale, P.K. Kulkarni, S. Shanmuganathan, Nanosponge carriers- an archetype swing in cancer therapy: a comprehensive review, Curr. Drug Targets 18 (2017) 108–118. [26] M. Ghosn, T. Ibrahim, T. Assi, E. El Rassy, H.R. Kourie, J. Kattan, Dilemma of first line regimens in metastatic pancreatic adenocarcinoma, World J. Gastroenterol. 22 (2016) 10124.
  26. 26. T.J. Hobday, R. Qin, D. Reidy-Lagunes, M.J. Moore, J. Strosberg, A. Kaubisch, et al., Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors, J. Clin. Oncol. 33 (2015) 1551.
  27. 27. R.R. Bhosale, H.V. Gangadharappa, D.V. Gowda, R.A. Osmani, R. Vaghela, P. K. Kulkarni, K.V. Sairam, B. Gurupadayya, Current perspectives on novel drug carrier systems and therapies for management of pancreatic cancer: an updated inclusive review, Crit. Rev. Ther. Drug Carrier Syst. 35 (2018).
  28. 28. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin. 68 (2018) 394–424
  29. 29. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699–708.
  30. 30. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634–38.
  31. 31. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifi es variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41: 986–90.
  32. 32. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101: 424–31.
  33. 33. Ojajärvi IA, Partanen TJ, Ahlbom A, et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000; 57: 316–24.
  34. 34. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies aff ect risk of pancreatic cancer. Gastroenterology 2009; 137: 482–88.
  35. 35. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009; 69: 3681–88.
  36. 36. Grover S, Stoff el EM, Bussone L, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004; 2: 813–19.
  37. 37. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25: 1417–22.
  38. 38. Vedat Goral, Pancreatic Cancer: Pathogenesis and Diagnosis, Asian Pacific Journal of Cancer Prevention, Vol 16, 2015;5619-5624
  39. 39. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/ gutjnl-2012-303108]
  40. 40. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620 [PMID: 21620466 DOI: 10.1016/S0140-6736(10)62307-0
  41. 41. Unger K, Mehta KY, Kaur P, Wang Y, Menon SS, Jain SK, Moonjelly RA, Suman S, Datta K, Singh R, Fogel P, Cheema AK. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget 2018; 9: 23078-23090 [PMID: 29796173 DOI: 10.18632/oncotarget.25212]
  42. 42. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181 [PMID: 19491823 DOI: 10.1038/ajg.2009.276]
  43. 43. Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol 2013; 27: 299-322 [PMID: 23809247 DOI: 10.1016/j.bpg.2013.04.001]
  44. 44. Lu C, Xu CF, Wan XY, Zhu HT, Yu CH, Li YM. Screening for pancreatic cancer in familial high-risk individuals: A systematic review. World J Gastroenterol 2015; 21: 8678-8686 [PMID: 26229410 DOI: 10.3748/wjg.v21.i28.8678]
  45. 45. Mills K, Birt L, Emery JD, Hall N, Banks J, Johnson M, Lancaster J, Hamilton W, Rubin GP, Walter FM. Understanding symptom appraisal and help-seeking in people with symptoms suggestive of pancreatic cancer: a qualitative study. BMJ Open 2017; 7: e015682 [PMID: 28871013 DOI: 10.1136/bmjopen-2016-015682]
  46. 46. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 2014; 4: e005720 [PMID: 25410605 DOI: 10.1136/bmjopen-2014-005720]
  47. 47. Xu J, Cao Z, Liu W, You L, Zhou L, Wang C, Lou W, Sun B, Miao Y, Liu X, Zhang T, Zhao Y. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Ann Surg 2016; 263: 1173-1179 [PMID: 26114496 DOI: 10.1097/SLA.0000000000001345]
  48. 48. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186 [PMID: 14731128 DOI: 10.1111/ j.1440-1746.2004.03219.x]
  49. 49. Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, etal. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst 2018 [PMID: 30137376 DOI: 10.1093/jnci/djy126]
  50. 50. Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 2018; 67: 128-137 [PMID: 28108468 DOI: 10.1136/ gutjnl-2016-312432]
  51. 51. Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY, Bidard FC. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol 2016; 10: 481-493 [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006]
  52. 52. Princivalle A, Monasta L, Butturini G, Bassi C, Perbellini L. Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air. BMC Cancer 2018; 18: 529 [PMID: 29728093 DOI: 10.1186/ s12885-018-4452-0]
  53. 53. Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 2013; 11: 719-30.e5 [PMID: 23200980 DOI: 10.1016/j.cgh.2012.11.016]
  54. 54. Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, Zhan HX. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer 2017; 141: 231-241 [PMID: 28240774 DOI: 10.1002/ijc.30670]
  55. 55. Lynch SM, Vrieling A, Lubin JH, Kraft P, etal. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413 [PMID: 19561064 DOI: 10.1093/aje/kwp134]
  56. 56. Demir IE, Jäger C, Schlitter AM, Konukiewitz B, Stecher L, Schorn S, Tieftrunk E, Scheufele F, Calavrezos L, Schirren R, Esposito I, Weichert W, Friess H, Ceyhan GO. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Ann Surg 2017 [PMID: 28692477 DOI: 10.1097/SLA.0000000000002345]
  57. 57. Kim KS, Kwon J, Kim K, Chie EK. Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancer Res Treat 2017; 49: 824-833 [PMID: 27561314 DOI: 10.4143/crt.2016.336]
  58. 58. Blamey SL, Fearon KC, Gilmour WH, Osborne DH, Carter DC. Prediction of risk in biliary surgery. Br J Surg 1983; 70: 535-538 [PMID: 6616158 DOI: 10.1002/bjs.1800700910]
  59. 59. Wang Q, Gurusamy KS, Lin H, Xie X, Wang C. Preoperative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2008; CD005444 [PMID: 18677779 DOI: 10.1002/14651858. CD005444.pub2]
  60. 60. Van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137 [PMID: 20071702 DOI: 10.1056/NEJMoa0903230]
  61. 61. 6Hua J, He Z, Qian D, Meng H, Zhou B, Song Z. Duct-toMucosa Versus Invagination Pancreaticojejunostomy Following Pancreaticoduodenectomy: a Systematic Review and Meta Analysis. J Gastrointest Surg 2015; 19: 1900-1909 [PMID: 26264363 DOI: 10.1007/s11605-015-2913-1]
  62. 62. Cheng Y, Briarava M, Lai M, Wang X, Tu B, Cheng N, Gong J, Yuan Y, Pilati P, Mocellin S. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev 2017; 9: CD012257 [PMID: 28898386 DOI: 10.1002/14651858.CD012257.pub2]
  63. 63. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012; 255: 1048-1059 [PMID: 22511003 DOI: 10.1097/ SLA.0b013e318251ee09]
  64. 64. Pericleous S, Middleton N, McKay SC, Bowers KA, Hutchins RR. Systematic review and meta-analysis of case-matched studies comparing open and laparoscopic distal pancreatectomy: is it a safe procedure? Pancreas 2012; 41: 993-1000 [PMID: 22836858
  65. 65. Zhang J, Wu WM, You L, Zhao YP. Robotic versus open pancreatectomy: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20: 1774-80 [PMID:23504140 DOI: 10.1245/ s10434-012-2823-3]
  66. 66. Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol 2010; 16: 818-831 [PMID: 20143460]
  67. 67. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, Weitz J. Arterial resection during pancreatectomy for pancreatic cancer. Ann Surg 2011; 254: 882-93 [PMID: 22064622 DOI: 10.1097/SLA.0b013e31823ac299]
  68. 68. Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, Jin C. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol 2014; 40: 371-378 [PMID: 24560302 DOI: 10.1016/ j.ejso.2014.01.010]
  69. 69. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481 [PMID: 24104372 DOI: 10.1001/ jama.2013.279201]
  70. 70. Neoptolemos JP, Stocken DD, Bassi C, etal. European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081 [PMID: 20823433 DOI: 10.1001/jama.2010.1275]
  71. 71. Neoptolemos JP, Palmer DH, etal; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024 [PMID: 28129987 DOI: 10.1016/ S0140-6736(16)32409-6]
  72. 72. . Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, JouffroyZeller C, Rat P, Castan F, Bachet JB. A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol 2018; 36: LBA4001-LBA4001 [DOI: 10.1200/JCO.2018.36.18_suppl.LBA4001]
  73. 73. Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D. Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol 2016; 8: 745-750 [PMID: 27795814 DOI: 10.4251/wjgo. v8.i10.745]
  74. 74. Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg 2017; 6: 167-174 [PMID: 28447006 DOI: 10.21037/acs.2017.03.16]
  75. 75. Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017; 17: 94 DOI: 10.1186/ s12893-017-0291-1]
  76. 76. Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY, Zhang GY. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med 2017; 6: 1201-1219 [PMID: 28544758 DOI: 10.1002/cam4.1071]
  77. 77. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol 2014; 20: 10740-10751 [PMID: 25152577 DOI: 10.3748/wjg.v20.i31.10740]
  78. 78. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, van Eijck CHJ, Groot Koerkamp B, Rasch CRN, van Tienhoven G; Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 2018; 105: 946-958 [PMID: 29708592 DOI: 10.1002/ bjs.10870]
  79. 79. Van Tienhoven G, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, de Hingh IHJT, Festen S, Patijn GA, de VosGeelen J, Zwinderman AH, Punt CJA, van Eijck CHJ. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol 2018; 36: LBA4002-LBA4002 [DOI: 10.1200/JCO.2018.36.18_suppl. LBA4002]
  80. 80. Conroy T, Desseigne F, Ychou M, Bouché O, etal; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
  81. 81. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J, El-Rayes BF. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42: 1311-1315 [PMID: 24152956 DOI: 10.1097/MPA.0b013e31829e2006]
  82. 82. Chu QD, Sun G, Pope M, Luraguiz N, Curiel DT, Kim R, Li BD, Mathis JM. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. Surgery 2012; 152: 441-448 [PMID: 22853858 DOI: 10.1016/j.surg.2012.05.040]